Sarcoma Foundation of America

Our 2027 Research Grant Cycle applications close tomorrow.

These grants support innovative and impactful research projects focused on basic, translational, pre-clinical, and clinical research on the etiology, pathogenesis, diagnosis, and treatment of human sarcomas.

SFA encourages applications in ALL areas of sarcoma research from U.S. and international applicants.

The total award amount is $75,000 for one year, July 1, 2027, to June 30, 2028.

For more information, please visit: buff.ly/Ze5rzcz

#Sarcoma #CureSarcoma #SarcomaResearch #SarcomaResearchFunding

Navigating a sarcoma diagnosis as a teen or young adult comes with unique challenges, and finding the right support can make a difference.

Join us next week for the first Live With the Experts education session in our two-part AYA sarcoma series, featuring expert insights and a patient perspective on navigating care, making treatment decisions, managing emotional well-being, and finding peer support.

Register: buff.ly/C6sGDtm

#Sarcoma #CureSarcoma #AYASarcoma #SarcomaEducation #SarcomaSupport

What does it take to show that a treatment works for people with a rare disease?

A petition submitted by the Haystack Project asks the FDA to consider evidence in the context of the disease and treatment being studied.

SFA’s experience illustrates why this matters. We submitted a letter to the FDA and participated in a meeting with a drug developer and the FDA about a potential approval pathway for a treatment being studied in two related sarcoma subtypes.

SFA provided sarcoma-specific expertise, focusing on whether the proposed study design offered an appropriate comparison and whether the outcomes measured would show meaningful benefits for patients. FDA representatives referenced SFA’s letter during the meeting.

In a recent Haystack Project case study, SFA CEO Brandi Felser shared how this experience shows the important role patient organizations can play in shaping how rare disease treatments are studied and evaluated.

Learn more: buff.ly/XkC0FYs

#Sarcoma #CureSarc #SarcomaAdvocacy

SFA is proud to serve as the Strategic Patient Advocacy Partner for the OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition.

Pan Pantziarka, our Director of Europe Strategy and Engagement, will represent SFA in bringing patient perspectives into scientific discussions to help advance more patient-centered sarcoma care.

Join us on October 29th for another Live With the Experts education session exploring fluorescence-guided surgery in sarcoma, including how the technique works, its potential applications, and the research evaluating its use. 

The discussion will cover how fluorescent dyes and special cameras help surgeons visualize tumors during surgery; the potential benefits and limitations of this approach; and the SarcoSIGHT clinical trial, including eligibility, where participation is available, and what participation involves. Our speakers will also discuss future directions, including emerging targeted imaging agents.

Register: buff.ly/jFM1OfG

#Sarcoma #CureSarcoma #SarcomaEducation